Lexaria Bioscience Corp. announced on January 14, 2025, partial final results from its human study GLP-1-H24-3. The study compared an oral version of DehydraTECH-processed Zepbound® (tirzepatide) to conventional injected Zepbound®.
Oral DehydraTECH-tirzepatide evidenced a 47% reduction in adverse events compared to injected Zepbound®. The injected drug produced 38 adverse events across 9 persons, while the oral formulation produced only 20.
Furthermore, the oral DehydraTECH-tirzepatide achieved comparable blood glucose reduction and insulin secretion levels to the injected Zepbound®. These findings highlight the potential for Lexaria's technology to offer a more tolerable and equally effective oral alternative to current injectable GLP-1/GIP drugs.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.